Search results

This joint initiative at ANSTO has developed a new capability: solid surface radiolabelling to evaluate Auger emitting sources for next-generation targeted therapy.

ANSTO’s Innovation Precinct welcomes NSW Government’s $12.5 commitment funding.

Bushfires in proximity to ANSTO during the 2018 bushfires.

Australia’s new state-of-the-art nuclear medicine facility gets green light.

See details of previously published customer updates from our Health products team. 

ANSTO to receive a new grant to continue to fight chronic kidney disease killer in Sri Lanka.

ANSTO offers a broad range of programs and services to various industries and customers. Many of these services, including the Australian Nuclear Medicine Traceability program, are supported by online customer portals.

This afternoon, the Chair of ANSTO, Dr Annabelle Bennett, wrote to all staff to let them know that CEO Dr Adi Paterson has decided to resign. She said the Board is deeply appreciative of the contributions Adi has made, including to the health, research and academic outputs of ANSTO during his tenure. Mr Shaun Jenkinson will continue as Acting CEO, while the Board undertakes a global search for a permanent CEO.

The Biological Small Angle X-ray Scattering beamline will be optimised for measuring small angle scattering of surfactants, nanoparticles, polymers, lipids, proteins and other biological macromolecules in solution. BioSAXS combines combine a state-of-the-art high-flux small angle scattering beamline with specialised in-line protein purification and preparation techniques for high-throughput protein analysis.